NCT00377234View on ClinicalTrials.gov

A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.

PHASE4CompletedINTERVENTIONAL

Enrollment

356

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions

Post Menopausal Osteoporosis

Interventions

DRUG

Risedronate

35mg po weekly for 12 weeks

DRUG

ibandronate [Bonviva/Boniva]

150mg po monthly for 3 months

Trial Locations (48)

16506

Erie

16635

Duncansville

19053

Feasterville

19114

Philadelphia

20817

Bethesda

23235

Richmond

23294

Richmond

28557

Morehead City

28562

New Bern

29621

Anderson

30060

Marietta

30134

Douglasville

30501

Gainesville

32952

Merritt Island

33024

Pembroke Pines

33409

West Palm Beach

33437

Boynton Beach

33458

Jupiter

33606

St. Petersburg

33614

Tampa

33777

Largo

34471

Ocala

34667

Spring Hill

34748

Leesburg

38120

Memphis

38375

Selmer

42431

Madisonville

44260

Mogadore

45224

Cincinnati

45236

Cincinnati

58401

Jamestown

59801

Missoula

68134

Omaha

72401

Jonesboro

74104

Tulsa

75231

Dallas

76021

Bedford

76502

Temple

77024

Houston

77030

Houston

77802

Bryan

85213

Mesa

85251

Scottsdale

92108

San Diego

92801

Anaheim

98105

Seattle

35294-3708

Birmingham

06708

Waterbury

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT00377234 - A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis. | Biotech Hunter | Biotech Hunter